SC 13G/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)

4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced it will sponsor and exhibit at the Florida Association of ACOs (FLAACOs) 2024 Annual Fall Conference, taking place in Orlando, FL, from November 20-22, 2024. The conference, hosted at the JW Marriott Orlando Bonnet Creek, brings together healthcare leaders and organizations focused on advancing value-based care models nationwide. At the event, Cardio Diagnostics will demonstrate how its innovative solutions align with ACOs' mission to deliver high-quality, cost-effective healthcare. The Company will showcase its comprehensive cardiovascular clinical solutions and data

Preliminary CMS pricing determination marks a key milestone in gaining broad access to Medicare reimbursement. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company today announced that the Company's PrecisionCHD and Epi+Gen CHD tests have received preliminary pricing determinations from the Centers for Medicare & Medicaid Services (CMS). This determination represents a crucial step toward securing Medicare reimbursement, enabling access to the Company's affordable, innovative, and highly scalable blood tests aimed at improving the risk assessment, diagnosis, management and monitoring of coronary heart disease (CHD) for Medicare patients.

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its redesigned website at CDIO.AI. This new site emphasizes the Company's AI-first approach and innovative scalable solutions for the prevention, detection and management of cardiovascular disease, which is the leading cause of death globally. This site also streamlines access to critical information and resources for investors, partners, patients, providers, and other key stakeholders. The redesigned website provides a significantly enhanced user experience, ensuring that each stakeholder group can easily navigate and find relevant information. Investor

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company's clinical blood test, Epi+Gen CHD is now available at Family Medicine Specialists' (FMS) retail clinical location at the Meijer Supercenter in McHenry, Illinois. Expanding Access in the Midwest Meijer, a privately owned and family-operated retailer based in Michigan, has more than 500 locations in the heartland of America. The company's consumers are predominately middle-aged and older adults in suburban and rural areas of the Midwest. Given that 73% of Meijer shoppers are within the Gen X and Boomers age groups of 45-years old and older, it is cruci

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum, taking place in Chicago, IL, from June 27-28, 2024. The Forum attracts senior executives from various healthcare sectors, including hospitals, health systems, health plans, and employer plans. The event is focused on enabling employers to build, launch, and optimize onsite clinical care facilities that are innovative and effective for their employees. Employee Onsite Clinics Drive Cost-Savings The prevalence of onsite clinics

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), a leader in AI-driven precision cardiovascular medicine, today announced the successful completion of its System and Organization Controls (SOC) 2 Type I audit, achieving compliance with the leading industry standards for customer data security. This milestone underscores the Company's unwavering commitment to the highest data security standards. "Achieving SOC 2 Type I compliance reflects our dedication to maintaining the trust of our clients and adhering to industry best practices," stated Tim Dogan, Ph.D., Chief Technology Officer of Cardio Diagnostics. "We take our responsibility seriously, and this accomplishment demonstrates our prior

Company to recommend pricing for its Epi+Gen CHD and PrecisionCHD tests, and pursue coverage via the Molecular Diagnostic Services (MolDx) program. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced its participation in the Clinical Laboratory Fee Schedule (CLFS) Annual Meeting on June 25, 2024. At this meeting hosted by the Centers for Medicare & Medicaid Services (CMS), the Company will recommend pricing for its innovative clinical tests to be considered for Medicare payment under the CLFS for calendar year 2025. At the CLFS Annual Meeting, Cardio Diagnostics will submit information and recommendations to support th

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company's clinical blood tests, Epi+Gen CHD and PrecisionCHD, are now available at Family Medicine Specialists' (FMS) newest clinical location at the Walmart Supercenter in Round Lake Beach, Illinois. FMS is a leading primary care and risk-bearing provider in Northern Illinois and in December 2023, launched the ongoing Heart Attack Prevention Initiative for at least 1,200 of their BlueCross BlueShield and other health plan patients. This launch in a retail healthcare setting is an expansion to existing and new patients in the area. Despite Walmart Health closin

The Peer-Reviewed Publication Demonstrates the Potential Economic Benefits of the PrecisionCHD™ Test for the Detection and Management of Coronary Heart Disease, which is One of the Largest Cost Centers for Public and Private Payers. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), a leader in the next generation of precision cardiovascular medicine technologies that combine proprietary AI algorithms with epigenetic and genetic biomarkers, today announced the publication of results from a budget impact modeling study for PrecisionCHD™, the Company's AI-powered multiomic coronary heart disease detection test. The peer-reviewed study "The Use of Precision Epigenetic Methods for the Diagnosis

Exponential Health, an innovative concierge medicine practice in Michigan, adopts Cardio Diagnostics' AI-driven epigenetic-genetic tests, marking a new era in personalized and preventive cardiac care. In a significant stride towards transforming cardiovascular healthcare in concierge specialty and primary care offices, Exponential Health, an innovative concierge medical practice led by Dr. William Baer, is set to offer Cardio Diagnostics Holdings, Inc.'s (NASDAQ:CDIO) clinical epigenetic-genetic cardiovascular tests, Epi+Gen CHD and PrecisionCHD, to their patients. As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease. Exponent

Mayumi Kitakata, a 57-year-old resident of Tokyo, Japan, is among the many pet owners who have turned to artificial intelligence to ensure the well-being of their furry companions. What Happened: Kitakata, who is concerned about the health of her 14-year-old cat, Chi, has adopted CatsMe!, an AI-driven smartphone application that claims to detect feline pain, reported Reuters. Kitakata, who has had cats since her mid-20s, uses the app to monitor Chi’s urinal activity and facial expressions. She believes that if she had used CatsMe! with her previous cat, Soran, she might have been able to detect his cancer earlier and potentially save him. See Also: Apple Analyst Says ‘You Don’t Wann

– SEC Filing

Benchmark analyst Bruce Jackson maintains Cardio Diagnostics Hldgs (NASDAQ:CDIO) with a Speculative Buy and raises the price target from $1.35 to $2.

Gainers Akanda (NASDAQ:AKAN) shares increased by 103.8% to $0.27 during Friday's regular session. The company's market cap stands at $8.6 million. NovaBay Pharmaceuticals (AMEX:NBY) shares rose 48.66% to $0.18. The company's market cap stands at $6.7 million. Pasithea Therapeutics (NASDAQ:KTTA) stock increased by 29.77% to $8.63. The company's market cap stands at $8.9 million. As per the news, the Q1 earnings report came out 3 days ago. TransCode Therapeutics (NASDAQ:RNAZ) stock moved upwards by 27.23% to $1.13. The market value of their outstanding shares is at $6.8 million. Onconetix (NASDAQ:ONCO) stock increased by 26.73% to $0.18. The market value of their outstanding shares is at

Gainers Novavax (NASDAQ:NVAX) stock increased by 110.7% to $9.42 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today. Portage Biotech (NASDAQ:PRTG) stock increased by 57.97% to $0.41. The market value of their outstanding shares is at $8.1 million. ITeos Therapeutics (NASDAQ:ITOS) stock rose 46.92% to $17.91. The company's market cap stands at $644.1 million. As per the press release, Q1 earnings came out today. Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 37.87% to $5.25. The company's market cap stands at $86.1 million. As per the press release, Q1 earnings came out yesterday. Cardio Diag

Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 34.7% to $27.44 during Friday's regular session. The market value of their outstanding shares is at $932.9 million. NKGen Biotech (NASDAQ:NKGN) stock increased by 19.76% to $1.03. The company's market cap stands at $23.4 million. The company's, Q4 earnings came out 3 days ago. Kintara Therapeutics (NASDAQ:KTRA) stock increased by 18.57% to $0.13. The market value of their outstanding shares is at $4.9 million. NeuroMetrix (NASDAQ:NURO) stock moved upwards by 17.26% to $4.28. The company's market cap stands at $8.5 million. Inspire Veterinary (NASDAQ:IVP) shares moved upwards by 17.24% to $0.05. The company's market cap stan